Purple Biotech (PPBT) Total Liabilities (2014 - 2026)

Purple Biotech (PPBT) has reported Total Liabilities for 13 consecutive years, with $2.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Liabilities fell 16.14% year-over-year to $2.0 million in Q2 2026; TTM through Jun 2026 was $2.0 million, a 16.14% decrease from a year earlier, with the FY2025 full-year figure at $7.9 million, up 91.74% from the prior year.
• Total Liabilities was $2.0 million for Q2 2026 at Purple Biotech, down from $4.8 million in the prior quarter.
• Over five years, Total Liabilities peaked at $10.0 million in Q4 2023 and troughed at $2.0 million in Q2 2026.
• A 5-year average of $6.0 million and a median of $6.2 million in 2022 frame the typical range for Total Liabilities.
• The widest YoY moves for Total Liabilities: up 91.74% in 2025, down 66.96% in 2025.
• Over 5 years, Total Liabilities stood at $7.5 million in 2022, then soared by 32.97% to $10.0 million in 2023, then plunged by 58.75% to $4.1 million in 2024, then jumped by 91.74% to $7.9 million in 2025, then sank by 75.32% to $2.0 million in 2026.
• The last three Total Liabilities figures came in at $2.0 million (Q2 2026), $4.8 million (Q1 2026), and $7.9 million (Q4 2025), per Business Quant data.